ID: ALA5189671

Max Phase: Preclinical

Molecular Formula: C16H19N

Molecular Weight: 225.33

Associated Items:

Representations

Canonical SMILES:  NC12CC3CC4c5ccccc5C(C1)C4(C3)C2

Standard InChI:  InChI=1S/C16H19N/c17-15-6-10-5-13-11-3-1-2-4-12(11)14(8-15)16(13,7-10)9-15/h1-4,10,13-14H,5-9,17H2

Standard InChI Key:  JTGSYLMMWSVQGE-UHFFFAOYSA-N

Associated Targets(non-human)

Glutamate NMDA receptor; Grin1/Grin2a 798 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 225.33Molecular Weight (Monoisotopic): 225.1517AlogP: 3.16#Rotatable Bonds: 0
Polar Surface Area: 26.02Molecular Species: BASEHBA: 1HBD: 1
#RO5 Violations: 0HBA (Lipinski): 1HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 10.54CX LogP: 2.35CX LogD: -0.44
Aromatic Rings: 1Heavy Atoms: 17QED Weighted: 0.72Np Likeness Score: 0.80

References

1. Turcu AL, Companys-Alemany J, Phillips MB, Patel DS, Griñán-Ferré C, Loza MI, Brea JM, Pérez B, Soto D, Sureda FX, Kurnikova MG, Johnson JW, Pallàs M, Vázquez S..  (2022)  Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.,  236  [PMID:35453065] [10.1016/j.ejmech.2022.114354]

Source